MRK May 2024 131.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:41AM EDT. Market open.
| Previous close | 2.3400 |
| Open | 2.6400 |
| Bid | 2.3900 |
| Ask | 3.4000 |
| Strike | 131.00 |
| Expiry date | 2024-05-17 |
| Day's range | 2.6400 - 2.6400 |
| Contract range | N/A |
| Volume | |
| Open interest | 381 |
ZacksMerck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
Business WireMerck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma
Simply Wall St.Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
© 2024 Yahoo. All rights reserved.